Recent Updates
Recently added Catalysts
VRTX Positive Sentiment

Vertex Reports Second Quarter 2026 Financial Results

Key Takeaway: Vertex Pharmaceuticals reported strong financial results for Q2 2026, highlighting significant revenue growth in cystic fibrosis, sickle cell disease, beta thalassemia, and acute pain. The company also updated its full-year revenue guidance positively. Additionally, the pending acquisition of Crinetics will expand its focus to rare endocrine diseases.

Market Sentiment Analysis

POSITIVE FACTORS

  • Strong revenue growth in multiple therapeutic areas.
  • Expansion of leadership in cystic fibrosis.
  • Pending acquisition of Crinetics to enhance portfolio.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
2.3%
average across 11 past catalysts
Lead asset
VX-880
Phase 3 · Diabetes Mellitus, Type 1

Full Press Release Details

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated(Nasdaq: VRTX) will report its second quarter 2026 financial results on Monday, August 3, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Second Quarter 2026 Earnings Call.”
The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website atwww.vrtx.comin the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis, and myotonic dystrophy type 1.
Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 16 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visitwww.vrtx.comor follow us onLinkedIn,Facebook,Instagram,YouTubeandX.
(VRTX-WEB)
Source:Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated Investor Relations:investorinfo@vrtx.com

Frequently Asked Questions

What were Vertex's Q2 2026 financial results?

Vertex reported strong financial results for Q2 2026, with significant revenue growth.

What is the focus of Vertex's pending acquisition?

The pending acquisition of Crinetics will enhance Vertex's portfolio in rare endocrine diseases.

Which areas showed revenue growth for Vertex?

Vertex experienced revenue growth in cystic fibrosis, sickle cell disease, beta thalassemia, and acute pain.

How did Vertex update its revenue guidance?

Vertex updated its full-year 2026 revenue guidance positively following strong Q2 results.

Last updated: Aug 3, 2026